Document text
Principal Investigator: John Daniel Kelly
Organization: VETERANS AFFAIRS MED CTR SAN FRANCISCO
Fiscal Year: 2022
Funding agency: Veterans Affairs
As SARS-CoV-2 vaccines enter mass distribution, little is known about vaccinated individuals who nonetheless
develop Covid-19 (symptomatic disease or “vaccine failure”), require hospitalization, and die. Pfizer-BioNTech
reported 3.8 vaccine failure cases/1,000 person-years, meaning vaccine failure will be relatively common on a
population level. Pfizer, Moderna, and Janssen vaccine efficacy trials involved 35,000 to 50,000 individuals
from which there are insufficient numbers to study vaccine failure, calling for post-vaccination surveillance with
observational cohort studies in real-world settings. Using the VHA Corporate Data Warehouse (CDW) and the
Covid-19 Shared Data Resource, we can harness real-time data to design a forward-thinking, active
surveillance system to pragmatically study the epidemiology of vaccine failure. Our overarching goals in the
proposed VAccine Failure study are to characterize post-vaccination Covid-19 clinical outcomes and
identify factors associated with vaccine failure. Our central hypothesis is that adverse Covid-19 clinical
outcomes after vaccination will be increasingly common over time, driven by delayed vaccination, clinical
factors associated with weak or rapidly declining immune responses, and viral lineages accumulating escape
mutations. We propose to identify a national longitudinal cohort of all Veterans age >65 years who had a
primary care visit in the VA within the past 2 years and received at least 1 dose of any SARS-CoV-2 vaccine
(N>1.55 million Veterans). We will observe these Veterans for up to 3.5 years and ascertain diagnoses of
Covid-19 incidence or vaccine failure (acute SARS-CoV-2 infection + at least 1 symptom), hospitalization, and
mortality. We will leverage our extensive experience conducting observational cohort studies with VA and
Medicare data to emulate a target trial approach and achieve the following Aims, rooted in the epidemiological
triad: Aim 1. To describe and compare Covid-19 clinical outcomes by vaccine type and manufacturer in a
population-based national cohort of SARS-CoV-2 vaccinated Veterans. Aim 2. To determine environmental
factors associated with vaccine failure. Aim 3. To determine host factors associated with vaccine failure. Aim
4. To determine agent factors associated with vaccine failure. To achieve Aim 4, we will use a case-control
study of 600 Veterans with Covid-19 to identify cases with the outcome of viral variant and perform density
sampling of controls from our SFVAHCS/VISN-21 catchment area, where we have access to banked remnant
SARS-CoV-2 PCR-positive samples. This project is uniquely positioned to provide the National VA Vaccine
Program with real-time evidence to rapidly adapt its vaccine delivery for Veterans (e.g., vaccine boosters for at-
risk groups; timing of next-generation vaccines) while filling the urgent national need for post-vaccination
surveillance in real-world settings.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Active Follow-up><Acute><Age><BMI><BMI percentile><BMI z-score><Body mass index><COVID-19><COVID-19 diagnosis><COVID-19 genome><COVID-19 infection><COVID-19 vaccination><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus genome><COVID19><COVID19 diagnosis><COVID19 genome><COVID19 infection><COVID19 vaccination><COVID19 vaccine><COVID19 virus><COVID19 virus genome><CV-19><CV19><Case-Base Studies><Case-Comparison Studies><Case-Compeer Studies><Case-Control Studies><Case-Referent Studies><Case-Referrent Studies><Catchment Area><Cirrhosis><Clinical><CoV-2><CoV2><Cohort Studies><Collaborations><Concurrent Studies><Data><Diabetes Mellitus><Disease><Disorder><Dose><Environmental Factor><Environmental Risk Factor><Epidemiology><Future><Genetic Alteration><Genetic Change><Genetic defect><Goals><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Healthcare><Hospital Admission><Hospitalization><Host Factor><Host Factor Protein><Immune response><Immune system><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Immunosuppressed Host><Incidence><Individual><Integration Host Factors><Israel><Laboratories><Long-term cohort><Longitudinal cohort><Longterm cohort><Manufacturer><Manufacturer Name><Medicare><Messenger RNA><Mutation><Natural History><Outcome><Pattern><Persons><Plant Roots><Population><Position><Positioning Attribute><Prevalence><Primary Care><Primary Health Care><Primary Healthcare><Protocol><Protocols documentation><Public Health><Quetelet index><RNA vaccine><RNA-based vaccine><Reporting><Risk><Risk Factors><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 diagnosis><SARS-CoV-2 genome><SARS-CoV-2 infection><SARS-CoV-2 infection history><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 genome><SARS-CoV2 infection><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Subgroup><Symptoms><System><Thinking><Time><Title 18><Triad><Triad Acrylic Resin><Triad resin><Vaccinated><Vaccination><Vaccinee><Vaccines><Variant><Variation><Veterans><Viral><Viral Genome><Viral Vector><Visit><Wuhan coronavirus><active followup><after COVID-19 infection><after SARS-CoV-2 infection><after SARS-CoV2 infection><after severe acute respiratory distress syndrome CoV-2 infection><ages><allergic/immunologic body system><allergic/immunologic organ system><booster dose><booster shot><booster vaccine><case-controlled studies><cirrhotic><clinical care><cohort><comparative><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 diagnosis><coronavirus disease 2019 genome><coronavirus disease 2019 infection><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus genome><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><data sharing networks><data sharing resource><data warehouse><deliver vaccines><density><design><designing><diabetes><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus 2019><diagnosed with coronavirus disease 2019><effectiveness study><efficacy trial><entire genome><environmental risk><epidemiologic><epidemiological><experience><follow up><follow-up><followed up><following COVID-19 infection><following SARS-CoV-2 infection><following SARS-CoV2 infection><following severe acute respiratory distress syndrome CoV-2 infection><followup><full genome><genome mutation><hCoV19><health care><health insurance for disabled><high risk><history of COVID infection><history of COVID-19 infection><hospitalization rates><host response><immune system response><immunoresponse><immunosuppressed patient><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interest><mRNA><mRNA vaccine><mRNA-based vaccine><military veteran><mortality><nCoV2><new vaccines><next generation vaccines><non vaccinated><not vaccinated><novel vaccines><outcome following vaccination><outcome following vaccine><plasmid vaccine><population based><post SARS-CoV-2 infection><previous COVID-19 infection><previous SARS-CoV-2 infection><previous SARS-CoV2 infection><previous severe acute respiratory distress syndrome CoV-2 infection><prior COVID-19 infection><prior SARS-CoV-2 infection><prior SARS-CoV2 infection><prior severe acute respiratory distress syndrome CoV-2 infection><programs><protective factors><response><result following vaccination><result following vaccine><root><severe acute respiratory syndrome coronavirus 2 diagnosis><severe acute respiratory syndrome coronavirus 2 genome><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><thoughts><unvaccinated><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination outcome><vaccination protocol><vaccination result><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine delivery><vaccine effectiveness><vaccine efficacy><vaccine failure><vaccine for novel coronavirus><vaccine outcome><vaccine protocol><vaccine result><vaccine study><vaccine trial><variants of concern><vector vaccine><veteran population><virus genome><whole genome>